Page 1,672«..1020..1,6711,6721,6731,674..1,6801,690..»

YMCA starting program to help residents with diabetes | News … – Lock Haven Express

Posted: February 16, 2017 at 7:40 am

PHOTO PROVIDED A class like this one to help residents at risk of diabetes will begin a 25-class series on March 2 at the Bellefonte YMCA.

BELLEFONTE It is one of the most slowly progressing diseases that often falls under the radar, but the YMCA of Centre County is starting a program to help prevent it.

Starting Thursday, March 2, from 6 to 7 p.m. at the Bellefonte YMCA, the YMCA of Centre County will be offering a diabetes prevention program that will consist of 25 class sessions throughout the year that will focus on topics that are crucial when it comes to diabetes prevention, such as nutrition and physical activity, according to Naomi Engelken, community health and wellness director at the State College YMCA.

Its really looking at preventing it from even happening, because we find that about one in three adults has prediabetes, meaning that theyre at high risk for developing type 2 diabetes, Engelken said. A program like this can reduce their risk of type 2 diabetes by about 58 percent.

Currently, there are more than 86 million adults in the United States who have prediabetes, and nine out of 10 are not aware that they have it, according to the Centers for Disease Control and Prevention (CDC).

Since last year, the YMCA of Centre County has been working toward implementing the diabetes prevention program, which started about 18 years ago as a study done by the CDC and the National Institutes of Health, Engelken said. Today, more than 200 YMCAs across the United States have implemented the program.

To qualify for the program, individuals must be at least 18 or older and have a BMI over 25 or be considered overweight, Engelken explained. The YMCA is also requesting that interested participants also get a blood test from their physician, as there is a certain blood value that indicates a high risk for developing type 2 diabetes.

There will be a cost to participate in the program, which will depend on a person-to-person basis, and the YMCA does offer financial assistance for the program, Engelken said. Most participants will receive an incentive to join the program, so if a participant is not a YMCA member, they will receive a YMCA membership for the duration of their participation in the program.

Engelken said that a typical class will consist of reviewing topics discussed in the previous class, looking at the weekly tracking of physical activity and nutrition, tracking weight, and afterward, participants will move onto the next educational topic. For the first four months of the program, there will be 16 weekly sessions, and the remaining nine will taper off into monthly maintenance sessions. Each session in the program will be an hour long, with sessions following the March 2 one being held on a rolling basis once at least eight people register for a session.

There are two main goals of the program to help individuals reduce their risk of diabetes. One is to reduce body weight by seven percent over the course of the program, and the other is to increase physical activity to an optimal level of 150 minutes per week, Engelken said.

The program will be unlike others and aims to have a lasting impact on participants lifestyles.

Because its a smaller environment, you have a supportive environment, you really get to know the people in the class, and it really allows you to kind of take control of your health versus someone leading you through an exercise program, Engelken said.

She added that the program will really focus on teaching individuals why they need to maintain these types of things so that they can have a healthy lifestyle, and it will allow them to carry on that lifestyle beyond the programs duration.

After the YMCA finishes with this years program, Engelken said that it plans to continue to help prevent diabetes in the community. The YMCA of Centre County has been working closely with the national YMCA office and they have a implementation program set for at least the next five years.

Theres no reason that so many people should be suffering from a disease like this when its preventable with relatively easy measures, Engelken said.

For program registration and/or inquiries about the program and financial assistance, please contact Naomi Engelken at either 814-237-7717 or nengelken@ymcaocc.org. People should register by Feb. 28.

LOCK HAVEN Lock Haven Hospital and its Board of Trustees will hold their annual public board meeting on Monday, ...

LOCK HAVEN Comcast Corp. has informed the City of Lock Haven that it will drop WTAJ-TV (channel 193) from its ...

TODAY r Spring Career Fair, 11 a.m. to 2 p.m., LHU Rogers Gymnasium. Information: Cortney Force at 570-484-2181 ...

Good day And happy birthday to Clay Graham of Beech Creek. Quote of the day The conventional army loses ...

See the original post:
YMCA starting program to help residents with diabetes | News ... - Lock Haven Express

Posted in Diabetes | Comments Off on YMCA starting program to help residents with diabetes | News … – Lock Haven Express

Sparta family raises diabetes awareness – The Sparta Independent

Posted: February 16, 2017 at 7:40 am

Published Feb 15, 2017 at 11:08 am (Updated Feb 15, 2017)

Chris Gildea, with sons Austin and Henry, volunteering at an American Diabetes Association event. Photo provided by Katie Gildea.

'); //-->

By Meghan Byers

SPARTA For the Gildea family, diabetes isn't just a disease; it's a daily battle. Sparta residents Katie and Chris Gildea, along with their two young sons, ages 3 and 7, will volunteer this June at the American Diabetes Association's upcoming Skylands Tour de Cure, an event which helps fund diabetes research. Chris Gildea, who has type 1 diabetes, has volunteered with the ADA for 10 years. This year, the Gildea family plans to help out at each Tour de Cure event in New Jersey.

"It's a 24-hours-a-day, seven-days-a-week job, living with diabetes," said Katie Gildea. "Diabetes robs you of your ability to lead a care-free life."

The Tour de Cure is the ADA's biggest fundraiser. The Skylands event, which will be held at Waterloo Village, will include both a cycling portion and "fun run & walk" for non-cyclists.

While raising money for a cure is a top priority, Katie Gildea believes that education is equally important, especially when it comes to confronting the social stigma often associated with diabetes.

"A lot of people don't realize that Type 1 diabetes is separate from Type 2 diabetes, and that anyone can have it. A lot of people think it's a choice," she said. "People always tell my husband, 'You look so healthy.' But diabetes doesn't look a certain way. It can affect anyone of any age, any lifestyle."

Chris Gildea, who works at Becton-Dickinson, a company that provides diabetes care products, enjoys an athletic lifestyle despite his disease. "My kids think he's a superhero," said Katie Gildea. "He always tells them never give up, never surrender, and that's how we are with this never give up, never surrender."

According to the ADA, 1.4 million Americans are diagnosed with diabetes each year, and approximately 1.25 million Americans have type 1 diabetes. In 2010, diabetes was the seventh leading cause of death in the United States.

"When you have something like this that can affect your children," said Katie Gildea, "you'll do anything in your power to rid the world of it."

The Skylands Tour de Cure will take place June 4 at Waterloo Village in Stanhope, with a kickoff event taking place on March 23 at Czig Meister Brewery in Hackettstown.

More information and event registration is available at http://www.diabetes.org/skylands, and anyone interested in volunteering can email Katie Gildea at katiehug@hotmail.com.

Continue reading here:
Sparta family raises diabetes awareness - The Sparta Independent

Posted in Diabetes | Comments Off on Sparta family raises diabetes awareness – The Sparta Independent

White Biotechnology Market Analysis By Product, By Application and … – Yahoo Finance

Posted: February 15, 2017 at 8:46 am

LONDON, Feb. 14, 2017 /PRNewswire/ -- The global white biotechnology market is expected to reach USD 487.08 billion by 2024, according to a new report by Grand View Research, Inc. Rising awareness and emphasis for the adoption of greener and environment-friendly technologies in various end-use industries is expected to drive the market over the next eight years.

Biofuels accounted for over 35% of the market in terms of revenue on account of rising government regulations to include the product in combination with conventional energy sources including diesel and gasoline. Growing product use in the agricultural sector is likely to drive the demand over the next eight years.

Rising biodiesel demand as a raw material for the manufacturing of resins, and polymers will fuel industry growth over the forecast period. Volatility of crude oil prices is expected to encourage various manufacturers in the market to increase biofuel production over the next eight years which in turn will propel technology demand.

Increasing technology use in the manufacturing of various high-value products such as base chemicals, consumer chemicals and specialty chemicals is expected to positively impact industry growth. In addition, rising concerns regarding depletion of oil reserves and non-degradability of synthetic resources derived from oil are expected to boost the adoption of this technology in various regions particularly North America and Europe.

Further key findings from the report suggest:

Global white biotechnology market demand was 203.28 billion in 2015 and is expected to grow at a CAGR of 10.2% from 2016 to 2024.

The biofuels segment is expected to grow at a CAGR of over 9% from 2016 to 2024. Advantages such as the ability to use directly in any unmodified diesel engine coupled with reduced particulate emissions are likely to fuel the growth of this industry over the next eight years.

Food and feed additives application are expected to register a CAGR of around 10% from 2016 to 2024 accounting for over 20% of the total revenue in 2015. Rising use of this technology in improving the texture, edibility and extending the shelf life of perishable food products is expected to drive the growth over the forecast period.

Biochemicals held the significant share, owing to its wide application scope in the chemical production process. Growing application scope of this technology on account of its use in efficient processing of chemicals is expected to drive the demand over the forecast period.

Asia Pacific accounted for a significant share of over 20% in 2015. The ready availability of biobased raw materials coupled with cheaper manufacturing costs is expected to fuel the growth. The region is also projected to witness a growth of over 8% from 2016 to 2024.

The industry is fragmented with a large number of major manufacturers present across the globe primarily in Europe and North America. Leading companies present in the global white biotechnology include DSM, Bayer, DSM, Evonik, Dow Chemicals, Henkel, BASF, DuPont, and LANXESS.

BASF is involved in manufacturing chemicals, performance products, plastics, oil & gas and crop protection products. The company has six business segments including plastics, gas exploration & production, chemicals, performance products, agricultural products and functional solutions. In March 2015, BASF along with eight other companies launched a project called PRODIAS (Processing Diluted Aqueous Systems) which focuses on optimizing various production processes for renewable products

Download the full report: https://www.reportbuyer.com/product/4230383/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

http://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/white-biotechnology-market-analysis-by-product-by-application-and-segment-forecasts-to-2024-300407371.html

Continued here:
White Biotechnology Market Analysis By Product, By Application and ... - Yahoo Finance

Posted in Biotechnology | Comments Off on White Biotechnology Market Analysis By Product, By Application and … – Yahoo Finance

Calcium imbalance within brain cells may trigger Alzheimer’s disease – Medical News Today

Posted: February 15, 2017 at 8:46 am

New research investigates the role of calcium production in Alzheimer's disease. The neurodegenerative process may be caused by a calcium imbalance within the brain cell.

Mitochondria - sometimes referred to as the "powerhouse of the cell" - are small structures that transform energy from food into cell "fuel."

In the mitochondria of a brain cell, calcium ions control how much energy is produced for the brain to function. Previous research has shown that an excessive production of calcium can cause neurons to die, therefore linking a calcium imbalance with the neurodegenerative process involved in Alzheimer's disease.

Until now, however, the exact mechanism that links Alzheimer's-related neurodegeneration and mitochondrial calcium imbalance was unknown. The new research - led by Pooja Jadiya, a postdoctoral fellow at Temple University in Philadelphia, PA - sheds light on this association.

The study was carried out by researchers from the Center for Translational Medicine at Temple University, and the findings were presented at the 61st Meeting of the Biophysical Society in New Orleans, LA.

Jadiya and colleagues studied brain samples from Alzheimer's patients, a mouse model genetically modified to replicate Alzheimer's-like symptoms, and a mutant Alzheimer's-affected cell line.

They examined the mitochondrial alterations in calcium processing, together with reactive oxygen species (ROS) generation, the metabolism of the active amyloid precursor protein, membrane potential, and cell death. They also looked at the activation of the mitochondrial permeability transition pores and oxidative phosphorylation.

In a healthy brain, calcium ions leave a neuron's mitochondria to prevent an excessive buildup. A transporter protein - called the mitochondrial sodium-calcium exchanger - enables this process.

In Alzheimer's-affected tissue, Jadiya and team found that the sodium-calcium exchanger levels were extremely low. In fact, the protein was so low that it was difficult to detect.

The researchers hypothesized that this would cause an overproduction of ROS, which would, in turn, contribute to neurodegeneration.

ROS are molecules that, in high levels, have been shown to damage proteins, lipids, and DNA, thus causing oxidative stress.

The team did find a correlation between the reduced activity of the sodium-calcium exchanger and increased neuronal death.

Additionally, in the mouse model, the scientists found that right before the onset of Alzheimer's, the gene that encodes the exchanger was significantly less active. A decrease in this gene's expression further suggests that the protein exchanger plays a key role in the progression of the disease.

Finally, the scientists also tested this mechanism in an Alzheimer's-affected cell culture model, by artificially boosting the levels of the exchanger.

As hypothesized, the affected cells recovered to a point where they were almost identical to healthy cells. Furthermore, the levels of adenosine triphosphate (ATP) increased, the ROS levels decreased, and fewer neurons died.

ATP is a molecule considered to be the "energy currency of life" by some biologists, as it is required by every activity our body engages in.

John Elrod, a co-author of the study, explains the significance of the findings:

"No one has ever looked at this before using these model systems. It is possible that alterations in mitochondrial calcium exchange may be driving the disease process."

The study may also pave the way for new treatment options, Elrod explains. The team is currently working to reverse the neurodegeneration typical of Alzheimer's disease in mouse models by stimulating the expression of the gene that encodes the sodium-calcium exchanger. This could be achieved with new drugs or gene therapy.

"Our hope is that if we can change either the expression level or the activity of this exchanger, it could be a viable therapy to use early on to perhaps impede Alzheimer's disease development - that is the home run," Elrod says. "We are not even close to that, but that would be the idea."

Learn how scientists can stop and reverse Alzheimer's-related brain damage in mice.

Written by Ana Sandoiu

Follow this link:
Calcium imbalance within brain cells may trigger Alzheimer's disease - Medical News Today

Posted in Cell Medicine | Comments Off on Calcium imbalance within brain cells may trigger Alzheimer’s disease – Medical News Today

Family Plans To Seek Compensation For Lacks’ Cells – CBS Local

Posted: February 15, 2017 at 8:46 am

February 14, 2017 5:15 PM By Marcus Washington

BALTIMORE (WJZ) The family of Henrietta Lacks issuing Johns Hopkins Medicine for using Lacks blood cells without her permission 66 years ago.

For years, Henriettas oldest son along with his son say they have been turned down by attorneys who have declined to help them because of the statute of limitation on the case. They now have an attorney who has agreed to help and take on John Hopkins.

The stories of Henrietta Lacks often surround her blood cells used by doctors to help create many medical advances for more than 60 years.

But to her oldest son, Lawrence, she is just mom.

I remember she was very strict and she was a very loving mother, said Lawrence Lacks.

At the age of 15, his world changed when his mother was diagnosed with cervical cancer.

I didnt know what it was all about, said Lacks. I [knew] I would have to stay home most of the time to take care of my brothers and sisters, because my father was taking her back and forth to Johns Hopkins all the time.

Within a year, Henrietta Lacks died, but her legacy would live on, not just with her family, but in the field of medicine.

Doctors at Johns Hopkins found that Henriettas cells were a type of immortal cell line that would later go on to help develop vaccines for many diseases, such at polio.

It wasnt until 2010, with the publishing of a book about Henrietta and her HeLa cells, that family members found out what had been going on for nearly 50 years.

Who wouldnt want their loved ones to have a cure for this or that, said Ron Lacks, Henriettas grandson.I mean, everybody was on board with that.

In a statement responding to Lacks familys claims, Johns Hopkins says in part:

Johns Hopkins Medicine celebrates and honors the incredible contribution to advances in biomedical research made possible by Henrietta Lacks.

Johns Hopkins never patented HeLa cells, and therefore does not own rights to the HeLa cell line. Johns Hopkins also did not sell or profit from the discovery or distribution of Hela cells.

Lacks family attorney, Francis Lanasa, thinks this goes beyond the money.

Fundamentally, its someone took someone elses property, and theyve continued to use that property to this day, said Lanasa. Its our understanding that the NIH (National Institutes of Health) and other entities have given Hopkins grants in the terms of hundreds of thousands of dollars to keep doing the research, so they have benefited financially by this.

Thats why we want to open our own foundation so we can get recognition for helping others, said Ron Lacks. You want to take control of your grandmothers legacy.

Follow @CBSBaltimore on Twitter and like WJZ-TV | CBS Baltimore on Facebook

Marcus Washington joined WJZ Eyewitness News in June 2014 as the weekend evening anchor and reporter. Dreams of becoming one of the people who tells the news came early for Marcus. He still remembers sitting in his living room at the age ...

Read the original:
Family Plans To Seek Compensation For Lacks' Cells - CBS Local

Posted in Cell Medicine | Comments Off on Family Plans To Seek Compensation For Lacks’ Cells – CBS Local

AJ Foyt planning to undergo stem-cell therapy – Indianapolis Star

Posted: February 15, 2017 at 8:45 am

Team owner A.J. Foyt watches his drivers during practice for the Indianapolis 500 on Monday, May 23, 2016, afternoon at the Indianapolis Motor Speedway.(Photo: Matt Kryger/IndyStar)Buy Photo

Racing legend A.J. Foyt is hoping to find the"fountain of youth."

The 82-year-old four-time winner of the Indianapolis 500 toldVerizon IndyCarmedia that he plans to undergo stem-cell therapy to help repair his ankles and shoulder. He also will have stem cells injected into hisblood.

Foyt's body has taken quite a beating over the years. According to the story, he suffered a broken back during a NASCAR race in 1964 and broken feet and legs during a 1991 IndyCar crash. In 2005, hewas stung more than 200 times by bees while trapped under his bulldozer at his Texas ranch. He's had knee and hip replacements, and in 2014 underwent triple-bypass heart surgery.

Foyt will undergo the therapy in Cancun, Mexico, as the treatment is not available in the United States.

It used to be you would have to go to Germany to get this procedure, but now it's available in Cancun and that is probably where I'll have it done, Foyt said Saturday during the Verizon IndyCar Series open test at Phoenix Raceway. I'm not in good health like I used to be and, if my son Larry hadn't taken over (running) the team four years ago, I would have had to shut it down. It's something he likes to do and I'm backing him 100 percent.

I feel better this year than I did last year, Foyt continued. If I get to feeling bad, I probably won't show up at the race. But I'm going to do that stem cell deal. My wife, Lucy, has been pretty sick lately. Dan Pastorini (the former NFL quarterback) did it and it helped him. Peyton Manning (the former Indianapolis Colts and Denver Broncos quarterback) did it for his neck and it really helped him. Tony Dorsett (the former Dallas Cowboys running back) did it, so I think we should try it.

Read the full story at indycar.com.

Autoplay

Show Thumbnails

Show Captions

Read the original:
AJ Foyt planning to undergo stem-cell therapy - Indianapolis Star

Posted in Cell Therapy | Comments Off on AJ Foyt planning to undergo stem-cell therapy – Indianapolis Star

Local stem cell researcher to appear on Dr. Oz today – Albany Times Union

Posted: February 15, 2017 at 8:45 am

From left are Dr. Oz, researcher Sally Temple, patient Patricia Holman, television personality Montel Williams and Dr. Elisabeth Leamy. (Courtesy Sony Pictures Television)

From left are Dr. Oz, researcher Sally Temple, patient Patricia Holman, television personality Montel Williams and Dr. Elisabeth Leamy. (Courtesy Sony Pictures Television)

From left are Dr. Oz, researchers Sally Temple, patient Patricia Holman, Dr. Elisabeth Leamy and television personality Montel Williams. (Courtesy Sony Pictures Television)

From left are Dr. Oz, researchers Sally Temple, patient Patricia Holman, Dr. Elisabeth Leamy and television personality Montel Williams. (Courtesy Sony Pictures Television)

Dr. Oz with Sally Temple, scientific director and co-founder of the Neural Stem Cell Institute. (Courtesy Sony Pictures Television)

Dr. Oz with Sally Temple, scientific director and co-founder of the Neural Stem Cell Institute. (Courtesy Sony Pictures Television)

Local stem cell researcher to appear on Dr. Oz today

Sally Temple has a plea for people considering stem cell therapy to cope with a chronic illness or life-threatening disease: Don't. Not yet.

Temple, co-founder of the Neural Stem Cell Institute in Rensselaer and president of the International Society for Stem Cell Research, has spent her career studying stem cells. Her pre-taped appearance on "The Dr. Oz Show" airs Tuesday, Feb. 14, where she talks about the difference between stem cell research and what she calls the "snake oil" promises of clinics that haven't been approved by the FDA but promise miracle cures for scourges like Alzheimer's and Parkinson's diseases.

Stem cells hold promise for treatment because they are the foundation from which all parts of the human body grow.

There are more than 500 clinics in the country offering unproven therapies, including some in New York state and a lot in Florida. "We know it's going on all around the world," Temple said.

Patients lured by false promises spend a lot of money. Temple said people have taken out second mortgages to cover the costs. But they are also at medical risk, Temple said, because injecting stem cells even the patient's own cells can have unpredictable results.

On TV

The Dr. Oz Show airs at 2 p.m. weekdays on NewsChannel 13 WNYT. Learn more about stem cell research at http://neuralsci.org.

"We're now hearing of people getting dreadful outcomes, tumors and blindness," she said.

It's because, without FDA approval and the long process of testing a new drug, there's no way to know for sure what's in the syringe, Temple said. "It may sound good to take stem cells from your own fat and inject them into your eye, but injecting stem cells that were good at making fat into another part of the body where they were never supposed to be can be disastrous."

Dr. Mehmet Oz said he chose this subject because there are stem cell clinics using the potential of legitimate research to take advantage of patients desperate for help.

"These physicians are violating not only the trust of their patients but also the law and hopefully our show will push the FDA to use its authority to shut them down," Oz said.

Temple said she was impressed by how informed Oz was during the taping for the show in New York City last month, and said it was clear the researchers and producers on the show had done their homework. Montel Williams, a former show host himself, also appeared on the segment. Williams suffers from multiple sclerosis and said he's been approached by clinics who want his celebrity endorsement.

"He was fully aware of lack of research and knew that when you dig for scientific rationale, it's not there," Temple said. "True stem cell therapy is coming, but we have to go through the proper channels and know it's safe."

See the original post here:
Local stem cell researcher to appear on Dr. Oz today - Albany Times Union

Posted in Cell Therapy | Comments Off on Local stem cell researcher to appear on Dr. Oz today – Albany Times Union

Abdominal fat may cause type 2 diabetes, heart disease – Medical News Today

Posted: February 15, 2017 at 8:43 am

Researchers have found that abdominal fat may either cause or relate to the cause of type 2 diabetes and coronary heart disease. People who are genetically at a greater risk of having a higher waist-to-hip ratio adjusted for body mass index are likely to have an increased risk of developing these conditions.

New research detailing these findings was published in JAMA.

Body mass index (BMI) is used to measure body fat based on height and weight, and it is a common method of working out whether a person is overweight or obese. Obesity is a major risk factor for both type 2 diabetes and coronary heart disease.

Regardless of BMI, body fat distribution can vary from one person to the next. Some people carry more fat around their visceral organs, called abdominal adiposity (fat), while others carry fat on their thighs and hips.

Previous observational studies have indicated that abdominal fat is associated with type 2 diabetes and coronary heart disease. However, it remains unclear whether these associations represent a causal relationship.

Dr. Sekar Kathiresan, of Massachusetts General Hospital in Boston, and colleagues conducted a study to investigate whether being genetically inclined to have an increased waist-to-hip ratio (WHR) adjusted for BMI (a measure of abdominal fat) was linked to cardiometabolic traits (such as lipids, glucose, insulin, and systolic blood pressure), and type 2 diabetes and coronary heart disease.

The team gathered data from four genome-wide association studies conducted between 2007 and 2015, which included up to 322,154 participants, and individual-level, cross-sectional data from the UK Biobank collected between 2007 and 2011, which included data from a further 111,986 people. Estimates for cardiometabolic traits were based on this combined data set.

Analysis did show that being genetically predisposed to a higher WHR adjusted for BMI was connected with increased levels of quantitative risk factors, including lipids, glucose, insulin, and systolic blood pressure, and a greater risk of developing type 2 diabetes and coronary heart disease.

Kathiresan and co-authors say that the results permit several conclusions. Firstly, the findings agree with previous studies that associate abdominal fat with cardiometabolic disease.

Secondly, the findings suggest that the distribution of body fat, beyond BMI measurement, could partly explain the disparity in risk of type 2 diabetes and coronary heart disease that is reported in both individuals and subpopulations.

"For example, increased abdominal adiposity at a given BMI has been proposed as an explanation for the excess risk of coronary heart disease observed in South Asians," the authors explain. "Similarly, greater abdominal adipose tissue at a given BMI has been proposed to underlie the excess risk of coronary heart disease at a given BMI among men compared with women," they add.

Lastly, WHR adjusted for BMI may lead to novel therapeutic strategies for the reduction of abdominal fat and decreasing the risk of type 2 diabetes and coronary heart disease.

"Although a substantial focus of drug development has been toward therapeutics to reduce overall adiposity, there has been little effort toward the development of therapies that modify body fat distribution to reduce abdominal adiposity," say the authors. Kathiresan and team conclude:

"These results provide evidence supportive of a causal association between abdominal adiposity and the development of type 2 diabetes and coronary heart disease."

Limitations of the study include the fact that there is a small chance that the findings from the study represent a "shared genetic basis" between WHR adjusted for BMI and coronary heart disease, instead of a causal relationship.

Learn how obesity may lead to heart attacks and stroke.

Read the original:
Abdominal fat may cause type 2 diabetes, heart disease - Medical News Today

Posted in Diabetes | Comments Off on Abdominal fat may cause type 2 diabetes, heart disease – Medical News Today

Type 1 diabetes: Reprogramming liver cells may lead to new treatments – Medical News Today

Posted: February 15, 2017 at 8:43 am

Researchers have discovered a way to reprogram mouse liver cells into precursor pancreatic cells by changing the expression of a single gene. They suggest that the finding is an important step toward showing that reprogramming liver cells might offer a way forward for the treatment of type 1 diabetes in humans.

The team - led by researchers from the Max Delbrck Center for Molecular Medicine in Berlin, Germany - reports the study in the journal Nature Communications.

Diabetes is a chronic disease that develops either when the body cannot make enough insulin, or when it cannot effectively use the insulin that it does make. Insulin is a hormone that regulates blood sugar, or glucose, and it helps to convert glucose from food into energy for cells.

Uncontrolled diabetes leads to high blood sugar, or hyperglycemia, which over time causes serious damage to many parts of the body, including the heart, blood vessels, nerves, eyes, and kidneys.

In the United States, an estimated 29.1 million people have diabetes, including 8.1 million who are undiagnosed.

The most common type of diabetes is type 2, in which the body cannot use insulin effectively. Type 1 diabetes, in which the body does not make enough insulin, accounts for around 5 percent of diabetes cases in adults.

The new study is likely to interest researchers developing treatments for type 1 diabetes. In people with type 1 diabetes, the immune system attacks the insulin-producing beta cells of the pancreas.

Researchers in regenerative medicine are exploring ways to generate new populations of pancreatic beta cells as a possible avenue for the treatment of type 1 diabetes.

Fast facts about type 1 diabetes

Learn more about type 1 diabetes

The new study concerns a method called cell reprogramming, in which it is possible to convert one type of cell into another type of cell, by tweaking genes.

An obvious source of cells for reprogramming into insulin-producing beta cells might be other types of cell in the pancreas.

In their study paper, the researchers mention other research that shows such pancreatic cells display a high degree of the necessary "cellular plasticity."

However, the researchers chose to focus on liver cells because, from a clinical perspective, they offer important advantages over pancreatic cells; for example, they are more accessible and abundant.

They also cite studies that have partially corrected hyperglycemia in diabetic mice by reprogramming liver cells into pancreatic beta cells.

The new study shows how just by changing the expression of a single gene called TGIF2, the team was able to coax mouse liver cells to take on a less specialized state and then stimulate them to develop into cells with pancreatic features.

When the researchers transplanted the modified cells into diabetic mice, the animals' blood sugar levels improved, suggesting the cells were behaving in a way similar to pancreatic beta cells.

The researchers identified TGIF2 (Three-Amino-acid-Loop-Extension homeobox TG-interacting factor 2) by running gene expression profiling tests on immature liver and pancreas cells isolated from mouse embryos as the cells differentiated toward their particular cell fates.

They found that at a particular differentiation branchpoint, the expression of TGIF2 changes in opposite directions as the cells commit to either liver or pancreatic fates.

The authors note that their study shows that "TGIF2 is a developmental regulator of pancreas versus liver fate decision," and when expressed in adult mouse liver cells, it suppresses the transcription program for liver cells and induces a subset of pancreatic genes.

There is still a lot of work to do to investigate whether the results with mice translate to humans. The team has already started working on human liver cells.

"There are differences between mice and humans, which we still have to overcome. But we are well on the path to developing a 'proof of concept' for future therapies."

Senior author Dr. Francesca M. Spagnoli, Max Delbrck Center

Learn how type 1 diabetes kills some insulin-producing cells but not others.

View post:
Type 1 diabetes: Reprogramming liver cells may lead to new treatments - Medical News Today

Posted in Diabetes | Comments Off on Type 1 diabetes: Reprogramming liver cells may lead to new treatments – Medical News Today

How Does Psoriatic Arthritis Affect Diabetes Risk? – Endocrinology Advisor

Posted: February 15, 2017 at 8:43 am


Endocrinology Advisor
How Does Psoriatic Arthritis Affect Diabetes Risk?
Endocrinology Advisor
The prevalence of diabetes is higher in patients with psoriatic arthritis (PsA), with greater PsA activity correlating with a higher risk of developing the disease, according to recent research published in The Journal of Rheumatology. Psoriatic ...

Visit link:
How Does Psoriatic Arthritis Affect Diabetes Risk? - Endocrinology Advisor

Posted in Diabetes | Comments Off on How Does Psoriatic Arthritis Affect Diabetes Risk? – Endocrinology Advisor

Page 1,672«..1020..1,6711,6721,6731,674..1,6801,690..»